Parallel Advisors, LLC Esperion Therapeutics, Inc. Transaction History
Parallel Advisors, LLC
- $4.87 Billion
- Q2 2025
A detailed history of Parallel Advisors, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 127,424 shares of ESPR stock, worth $189,861. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,424
Previous 10,000
1174.24%
Holding current value
$189,861
Previous $15,000
726.67%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ESPR
# of Institutions
202Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$20.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$17.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$16.3 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$14.4 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$10.3 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $99.2M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...